Abstract: The present disclosure provides a method of receiving system information by a user equipment in a wireless communication system. Particularly, the method may include receiving a Physical Downlink Control Channel (PDCCH) including Downlink Control Information (DCI) for scheduling the system information; descrambling a Cyclic Redundancy Check (CRC) of the DCI based on a System Information-Radio Network Temporary Identifier (SI-RNTI); obtaining first information on a type of the system information from a specific bit included in the DCI; receiving the system information based on second information for scheduling the system information, which is included in the DCI; and determining the type of the system information based on the first information.

Abstract: The present invention discloses a method for a terminal to receive a synchronization signal in a wireless communication system. Particularly, the method includes the steps of receiving a synchronization block including a primary synchronization signal (PSS), a secondary synchronization signal (SSS), and a physical broadcasting channel (PBCH) and receiving a DMRS (demodulation reference signal) via resource region in which the PBCH is received. In this case, an index of the synchronization block can be determined in consideration of a sequence of the DMRS.

Abstract: The present disclosure provides a method of transmitting a Physical Broadcasting Channel (PBCH) by a base station in a wireless communication system. Particularly, the method may include generating a PBCH payload including bits indicating a frame in which the PBCH is transmitted; scrambling at least some of the bits included in the PBCH payload using second and third least significant bits among the bits; and transmitting the bits of the PBCH payload including the at least some scrambled bits to a user equipment.

Abstract: The present disclosure relates to an anti-FcRn antibody or an antigen binding fragment thereof with improved stability and uses thereof. The anti-FcRn antibody or antigen binding fragment thereof binds to FcRn non-competitively with IgG and the like compared to the parent antibody, HL161AN, thereby having improved stability, such as reducing the production rate of aggregates while maintaining the biological activity of significantly reducing the amount of pathogenic autoantibodies in the blood. Therefore, it may be utilized more efficiently for the treatment of an autoimmune disease.

Abstract: Anti-inflammatory compounds are useful, for example, in treating arthritis and heart attack patients. Novel oligosaccharides useful in the rapid synthesis of certain anti-inflammatory compounds are disclosed, as is a rapid method of synthesizing the oligosaccharides. Low pH can loosen the acceptor specificity of galactosyltransferase (lactose synthase: EC 2.4.1.22), allowing the rapid synthesis of novel oligosaccharides. The disaccharides cellobiose (.beta.1.fwdarw.4), laminaribiose (.beta.1.fwdarw.3), gentiobiose (.beta.1.fwdarw.6) and maltose (.alpha.1.fwdarw.4) acted as acceptors for lactose synthase under low pH conditions. From these four acceptors, the following four novel trisaccharides were synthesized: Gal.sub.p (.beta.1.fwdarw.4)Glc.sub.p (.beta.1.fwdarw.3)-Glc, Gal.sub.p (.beta.1.fwdarw.4)Glc.sub.p (.beta.1.fwdarw.4)-Glc, Gal.sub.p (.beta.1.fwdarw.4)Glc.sub.p (.beta.1.fwdarw.6)-Glc and Gal.sub.p (.beta.1.fwdarw.4)Glc.sub.p (.alpha.1.fwdarw.4) Glc.

Abstract: Anti-inflammatory compounds are useful, for example, in treating arthritis and heart attack patients. Novel oligosaccharides useful in the rapid synthesis of certain anti-inflammatory compounds are disclosed, as is a rapid method of synthesizing the oligosaccharides. Low pH can loosen the acceptor specificity of galactosyltransferase (lactose synthase: EC 2.4.1.22 ), allowing the rapid synthesis of novel oligosaccharides. The disaccharides cellobiose (.beta.1.fwdarw.4) , laminaribiose (.beta.1.fwdarw.3) , gentiobiose (.beta.1.fwdarw.6) and maltose (.alpha.1.fwdarw.4) acted as acceptors for lactose synthase under low pH conditions. From these four acceptors, the following four novel trisaccharides were synthesized: Gal.sub.p (.beta.1.fwdarw.4)Glc.sub.p (.beta.1.fwdarw.3)-Glc, Gal.sub.p (.beta.1.fwdarw.4)Glc.sub.p (.beta.1.fwdarw.4)-Glc, Gal.sub.p (.beta.1.fwdarw.4)Glc.sub.p (.beta.1.fwdarw.6)-Glc and Gal.sub.p (.beta.1.fwdarw.4)Glc.sub.p (.alpha.1.fwdarw.4)Glc.